"March 19, 2012 -- Three generic drugmakers may now sell their own versions of the bone-loss drug Boniva, the FDA ruled today.
Boniva, known by the generic name ibandronate, is a once-a-month pill prescribed to prevent or to treat bone"...
No specific information is available on the treatment of overdosage of BONIVA. However, based on knowledge of this class of compounds, oral overdosage may result in hypocalcemia, hypophosphatemia, and upper gastrointestinal adverse events, such as upset stomach, dyspepsia, esophagitis, gastritis, or ulcer. Milk or antacids should be given to bind BONIVA. Due to the risk of esophageal irritation, vomiting should not be induced, and the patient should remain fully upright. Dialysis would not be beneficial.
BONIVA is contraindicated in patients with the following conditions:
- Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia (see WARNINGS AND PRECAUTIONS)
- Inability to stand or sit upright for at least 60 minutes (see DOSAGE AND ADMINISTRATION, and WARNINGS AND PRECAUTIONS)
- Hypocalcemia (see WARNINGS AND PRECAUTIONS)
- Known hypersensitivity to BONIVA or to any of its excipients. Cases of anaphylaxis have been reported. (see ADVERSE REACTIONS).
Last reviewed on RxList: 1/5/2015
This monograph has been modified to include the generic and brand name in many instances.
Additional Boniva Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get tips and advances in treatment.